Leukocyte adherence deficiency (LAD) is an inherited immunodeficiency disease caused by defects in the CD18 leukocyte integrin subunit. Transduction of CD18 into hematopoietic cells from children with LAD represents a potential therapy for this disorder. In an attempt t o maximize transfer and expression of CD18, we evaluated retroviral vectors with and without the neomycin selectable marker, with a modified tRNA primer binding site designed t o prevent inhibition of gene expression, and with two different viral envelope proteins produced by using the amphotropic retrovirus packaging cell line PA317 or the gibbon ape leukemia virus packaging cell line PG13. The vectors were tested using transducing K562/CDIlb cells and LAD Epstein-Barr virus (EBV) B cells and measuring levels of cell-surface CD1 1/CD18 expression by fluorescence-activated cell sorter analysis. The best results were obtained with vectors made using PG13 packaging cells, for which about 25% of the K562 cells exposed once to the vectors expressed surface CDllb/CD18 and about 25% of the LAD EBV B cells exposed three times over a 3-day period t o the vectors expressed surface CD1 lalCD18.
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HILDREN WITH LEUKOCYTE adherence deficiency (LAD) experience recurrent, life-threatening bacterial infections due to the inability of their leukocytes to adhere to the blood vessel wall and migrate to the site of infection. ' The clinical manifestations of the disease stem from the inability of leukocytes from affected children to express the four heterodimeric members of the leukocyte integrin family: CDlldCD18 (LFA-l), CDllb/CD18 (Mac-l), CDllc/ CD18 (~150,95),2.~ and CDlld/CD18.3a Previous experimental studies have shown that the CD11 subunits are intrinsically normal in LAD and that defects in the common CD18 subunit are responsible for the inability to express the CD1 l / CD18 complexes on the leukocyte surface. zd We and others have studied the feasibility of using retroviral vectors to restore CD18 expression in cells from LAD patients, with the ultimate goal of long-term disease correction by CD18 gene transfer into hematopoietic stem cells. However, previous studies on retrovirus-mediated CD1 8 gene transfer have shown relatively low CD18 gene transfer rates and low expression levels in cultured cell^.^" In our studies using the LCD18SN retroviral vector, produced by using PA317 amphotropic retrovirus packaging cells, gene transfer into Epstein-Barr virus (EBV)-immortalized LAD B cells required cocultivation of the target cells with the vector-producing line. Additionally, despite several weeks of selection in (2418, the LAD EBV B cells transduced with the retroviral vector expressed only 5% to 10% of the normal surface levels of CD1 K D 1 8 heter~dimer.'.~
In an attempt to improve gene transfer efficiency and gene expression levels, we have tested two modifications to the previously used LCD18SN retroviral vector. First, we have replaced the Moloney murine leukemia virus (MoMuLV) proline tRNA binding site in the CD18 vector with a glutamine tRNA binding site from an endogenous mouse virus. ' The tRNA binding site is required during the first steps in In contrast, transduction of cells under similar conditions with retroviral vectors produced using PA317 producer cells yielded less than 2% of the K562 cells and less than 4% of the LAD EBV B cells expressing the CD1 1/CD18 heterodimer on the cell surface. The presence or absence of the neomycin resistance gene or the modified tRNA primer had no effect on CD18 gene transfer rate or expression level. The increase in transduction with PG13 vectors correlated with Northern blotting and reverse transcription-polymerase chain reaction studies that indicated that both K562 cells and the LAD EBV B cells express transcripts for the gibbon ape leukemia virus receptor at higher levels than for the amphotropic virus receptor. These findings indicate that the transduction efficiency of retroviral packaging cell lines correlates with receptor gene expression in the target cells and that vectors made using PG13 cells may be efficacious for gene therapy for LAD and other diseases in which gene transfer t o hematopoietic cells is required. 0 1995 by The American Society of Hematology.
reverse transcription of the retroviral vector. Unrelated to this function, the normal MoMuLV tRNA binding site also can bind a cellular protein that causes repression of transcription from the retroviral long terminal repeat (LTR) in embryonic carcinoma and other cell types?." Substitution of the glutamine site for the normal proline tRNA binding site abolishes this inhibition while still allowing proper reverse transcription of the vector.")." Second, we have investigated whether removal of the neomycin resistance (neo) gene present in the LCD18SN vector would result in increased CD18 expression. This approach was based on reports that ne0 gene sequences can inhibit expression from nearby promoters" and that the presence of two transcriptional units within a retroviral vector may cause mutual interferen~e.'~ In addition, the neo gene product might stimulate immune responses 2380 BAUER, MILLER, AND HICKSTEIN in the context of human gene therapy or cause inappropriate protein phosphorylation; thus, removal of the gene would be advantageous provided that gene transduction efficiencies were at least as high as vectors that encode selectable markers.
We have also tested whether substitution of the gibbon ape leukemia virus (GALV)-derived retrovirus packaging cell line PG13 for the amphotropic PA317 cell line that was previously used to produce the LCD18SN vector might result in improved transduction efficiency in hematopoietic cells. The key difference between these two packaging cell lines is the viral envelope protein incorporated into the retroviral vector particles. Cell-surface receptors that interact with retroviral envelope proteins to allow entry of GALV or amphotropic retroviruses have now been ~l o n e d , '~"~ and the GALV receptor is highly expressed in bone marrow, while the amphotropic receptor is expressed at low levels in bone mar-
The results of these studies indicate that, although vector modifications involving the primer binding site and removal of the neo gene did not influence CD18 expression levels in vector-transduced hematopoietic cells in short-term in vitro assays, the use of PG13 GALV-derived retrovirus packaging cells allowed more efficient gene transfer into both K562 and LAD EBV B cells than did PA3 17 amphotropic packaging cells and allowed direct transduction of the target cells by exposure to vector-containing medium. The levels of CD18 expression in transduced LAD EBV-immortalized lymphocytes were similar to CD18 expression levels in normal lymphocytes. These studies support the use of retrovirus-mediated gene therapy for LAD by using retroviral vectors produced by PG13 cells.
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MATERIALS AND METHODS
Cell culture. The retroviral packaging cell lines PG13,18 PA317,I9 and PE501"; the chronic myelogenous leukemia (CML) cell line K562"; and Cf2Th canine thymus cells" were grown in Dulbecco's modified Eagle medium (BioWhittaker, Wallcersville, MD) with high glucose (4.5 gL) and supplemented with 10% fetal bovine serum (FBS; GIBCO-BRL, Grand Island, NY). The EBVimmortalized B-cell lines derived from LAD patients (A, Gb,6 Gs, J, and Z4) were grown in RPM1 1640 (BioWhittaker) supplemented with 10% FBS. All cells were grown at 37°C in a 10% COz atmosphere. Selection for neomycin phosphotransferase expression was performed with 1 m g h L Geneticin (G418 Sulfate; GIBCO-BRL; approximately 67% active product) as described." Retroviral vector construction. The retroviral vector LgCDl8SN was constructed by cloning the 3.6-kb Spe YHindIII fragment from LCD18SN' containing the extended packaging region, CDIS, and SV40 promoter into Spe YHindIII-digested retroviral vector LgXSN Vector production and assay. To generate retroviral vectors for gene transduction, 10 pg of plasmid DNA from LgCD18SN was transfected into PE501 cells using calcium phosphate precipitation.20 Supernatant from the transfected PE501 cell line was used to transduce both PA317 and PG13 cells. Twelve (3418-resistant clones were isolated from each of the transduced PA317 and PG13 packaging cell lines. DNA was extracted from the individual clones and examined for rearrangements on Southern blots. The LCD18SN vector was constructed and introduced into PA317 cells as previously de~cribed.~ Virus from these cells was used to transduce PG13 cells. The resulting (3418-resistant colonies were pooled. Retroviral vectors from LgCD18 were produced by cotransfection of 10 kg of plasmid DNA from LgCDl8 with 0.1 pg of pSV2neo into PG 13 cells by calcium phosphate precipitation. Thirty-two G41 8-resistant clones were isolated.
For vector production, medium was harvested from confluent monolayers of the vector-producing cell lines 12 to 24 hours after the addition of fresh medium. The titers of vectors carrying the neo gene were determined using Cf2Th canine cells as targets for transduction, because these cells are susceptible to transduction by vectors produced by either PA317 or PG13 cells. The Cf2Th cells were seeded at 105 cells per 6-cm dish on day 1. infected with a range of virus dilutions in the presence of 4 pglmL polybrene on day 2, exposed to 670 pg/mL G418 (active concentration) on day 3, and counted after staining on day 8.
Flow cytometry assay for CD18 expression from retroviral vectors. K562 cells were transfected with an episomal vector pREP4 (Invitrogen, San Diego, CA)/CDllb in which the CDllb subunit was inserted downstream of the Rous sarcoma virus promoter present in the plasmid. pREP4/CDllb also contains the hygromycin resistance cDNA expressed from the SV40 promoter." Bulk cultures of hygromycin-resistant cells were obtained and used for these studies. The K562/CD1 l b cell line will express the CD1 Ib/CDI8 heterodimer on the surface when transduced with vectors containing CD18, and this surface expression can be analyzed by fluorescence-activated cell sorting (FACS). For this assay, 2 X 10' K562/CD1 l b cells were transduced with 1 mL of supernatant from each CD18 producer clone in the presence of 4 pg/mL polybrene. Two and one half days after transduction, the cells were analyzed for CD1 I bl CD18 surface expression using indirect immunofluorescence followed by flow cytometry. Monoclonal antibodies (MoAbs) directed against an irrelevant antigen (the MoMuLV ecotropic envelopeMoAb 9E8)," the CDllb subunit (MoAb 60.1)," and the CD18 subunit (MoAb 60.3),26 served as the primary antibodies in this assay. Cells were analyzed by flow cytometry on a Becton Dickinson FACScan (Becton Dickinson, Mountain View, CA).
Transduction of LAD EBV B cells. LAD EBV B cells derived
from a patient (Z) with the severe deficiency form of LAD (expressing no detectable CD18 RNA or protein4) were used in the retroviral vector comparison studies. In these assays, 2 X IO5 cells were transduced in a 24-well plate with 1 mL of viral supernatant from either PG13LgCD18SN c54, PA317LgCD18SN c35, PG13LCD18SN3
or PG13LgCD18 cl1 cells in the presence of 4 pg/mL polybrene. After 24 and 48 hours, the plates were centrifuged at 1,500 rpm for 5 minutes, the supernatant was carefully aspirated and discarded, and 1 mL of fresh viral supernatant was added along with 4 p g b L polybrene. Cells were harvested after approximately 72 hours and analyzed by FACS. Transduced LAD EBV B cells were immunostained with MoAbs 9E8, R3.1 (which recognizes CDlla''), and 60.3.
For studies examining the transduction capability of five different LAD EBV B-cell lines, 5 x lo5 cells from each cell line were transduced separately (day 0) in a 24-well plate with 1 mL of viral supernatant from PG13LgCD18SN c54 cells and 4 pg/mL polybrene. On days I, 3, and 4, the plate was centrifuged, the transduced cells' supernatant was carefully aspirated and discarded, and 1 mL of fresh viral supernatant was added along with 4 pg/mL polybrene. On day 5, 1 mL of RPM 1640 medium containing 10% FBS was added to each well. Cells were expanded for 1 week and were examined by FACS analysis.
Assay of retrovirus recepfor franscripfs. RNA samples from K562/CD1 l b cells and LAD EBV B cells were reverse transcribed with Superscript reverse transcriptase (GIBCO-BRL) according to the manufacturer's directions using oligo dT or random hexamers. Each cDNA was used in a polymerase chain reaction (PCR) containing 100 ng of forward primer (5'"ITCCAG'ITCCTG-CAGGTCCT-3') and reverse primer (5'-TCC'ITCCCCATGGTCT-GGAT-3'), l x Vent buffer, 0.2 mmoVL M P S , and 2 U Vent polymerase (NEB, Beverly, MA). The reaction was performed in a Perkin Elmer GeneAmp PCR system 9600 thermocycler (Perkin Elmer, Foster City, CA) with cycling parameters of 94°C for 1 minute; 5 cycles of 94°C for 15 seconds, 55°C for 15 seconds, and 72°C for 15 seconds; 30 cycles of 94°C for 15 seconds and 60°C for 30 seconds; and a final extension of 60°C for 5 minutes. The forward primer differs by one base each from the Glvr-l (A to G at base 16) and Ram-l (T to G at base 6) cDNAs, whereas the reverse primer is identical to Glvr-l and Ram-l. Reaction products were precipitated with ethanol in the presence of 20 pg glycogen and end-labeled with PS' using T4 Polynucleotide kinase (Promega, Madison, WI). The labeled products were digested with Hae III for 2 hours, put through Nuctrap columns (Stratagene, La Jolla, CA), reprecipitated, and resuspended in 10 pL H'O. A total of 5 pL was added to 1 pL of loading dye, and 2.5 bL of the dye/sample mix was electrophoresed on a 6% nondenaturing acrylamide gel at 2,000 V, 50 W for 2 to 3 hours. The gel was fixed in a 12.5% methanol/ 12.5% acetic acid bath, transferred to Whatman paper (Whatman, Hillsboro, OR), dried, and exposed overnight to an x-ray film.
Northern blots. RNA samples from K56UCD1 l b cells and LAD EBV B cells were electrophoresed in denaturing formaldehyde gels, followed by positive pressure blotting onto a Zetaprobe GT (BioRad, Hercules, CA) nylon membrane filter. The filter was hybridized to a P'-labeled Glvr-l cDNA probe (a 227-bp fragment [bases 1913 to 2139 in OHara et all4] specific for human Glvr-l), followed by stripping and rehybridization with a GAPDH probe as previously performed?'
RESULTS
Construction
of modiJied CD18 retroviral vectors. The CD18 subunit was cloned into a retroviral vector containing a modified tRNA primer binding site to create the retroviral vector LgCD18SN. This vector is otherwise identical to the previously described LCD18SN (Fig 1) . The LgCD18SN vector was produced by using either the amphotropic packaging cell line PA317I9 or the GALV packaging cell line PG13.l' Vector titers were determined using Cf2Th canine cells as targets for transduction (Table 1) . Titers ranged from 4 X io3 to 4 X IO5 colony-forming units (CFU)/mL. Of note, although PG13LgCD18SN c49 had one of the highest titers, this clone was found to be rearranged on Southern blotting. The LgCD18 vector is essentially the LgCD18SN vector without the SV40 promoter driving the neo gene and was packaged only in PG13 cells. Because neo was not present in this vector, relative vector titers were determined by the ability of the virus to transfer CD18 to K5621CD1 l b cells (as described below), and the best vector-producing clone (clone 11) of 32 clones tested was used for further experiments. Development of a CDII/CD18 complementation assay. To functionally assay the CD18-containing retroviral vectors, we transduced K5621CDllb cells and measured CDllb1CDl8 expression levels by FACS analysis. K562/ CD1 1 b cells will produce a functional CD1 IbKD18 heterodimer on transduction with a CD18-containing retroviral vector.23 The transduction efficiency and expression of almost all of the PG13 producer clones (up to 24%) exceeded the levels achieved with the PA317 producer clones (all <2%; Table 1 ).
The transduction results obtained with viral supernatants from PA317ngCD18SN c35 and PG13LgCD18SN c54 are displayed (Fig 2) . FACS analysis of cells transduced with supernatant from PA317ngCD18SN c35 cells indicated a low (<2%) but detectable percentage of positive cells (Fig 2,  row 3) . In contrast, analysis of K56UCD1 l b cells transduced with virus from PG13LgCD18SN c54 showed the presence of a discrete population of CD1 lb1CD18-positive cells (Fig  2, row 4 ). This population of cells constituted approximately 24% of the total number of cells. This system provides evidence for transfer of a CD l8 protein capable of heterodimer formation and surface expression.
Transduction of EBV-immortalized LAD B cells. Previ-
ous studies indicated that CD1 1 complementation by the CD18 gene could occur in EBV-immortalized LAD B cells after transduction with a retroviral vector harboring the CD18 subunit.' To examine for the expression of the CD18 gene with our new retroviral vectors, we transduced an LAD EBV B-cell line ( Z ) derived from a patient whose leukocytes do not express CD18 at the protein or RNA leveL4 Transduction of these cells with virus from PA3 17LgCD18SN c35 resulted in only 3% to 4% positive cells by FACS (Fig 3,  row 2 ). Transduction and expression with virus from PG131 LgCD18SN c54 resulted in approximately 15% positive cells (Fig 3, row 3 ). The level of CDlldCD18 expressed on the cell surface of the positive cells was similar to that present on EBV-immortalized normal B cells (Fig 3, row 4) .
Comparison of LgCDl8, LgCD18SN, and LCD18SN vectors. Our previous studies used the retroviral vector LCD18SN to correct the CD18 gene defect in LAD EBV B To ensure the conditions for transduction were comparable, both vectors were produced using PG13 packaging cells. FACS analysis showed that the cells transduced by each retroviral vector had approximately equal levels of surface expression of CD18 (Fig 4, rows 1 and 2) . The percentage of transduced cells ranged from 20% for LgCD18SN to 26% for LCD18SN. Additionally, we examined the effect of neo gene removal on CD18 gene expression by comparing the LgCD18 and LgCD18SN vectors. Previous have indicated deleterious effects of the neo gene within a retroviral vector or promoter interference from the presence of a second promoter. FACS analysis of cells transduced (21% transduced) with the LgCD18 vector (Fig 1) showed little difference in fluorescent intensity as compared with cells transduced with the LgCD18SN or LCD18SN vectors (Fig   4, row 3) . These results indicate that neither the presence of the ne0 gene nor the modification of the tRNA PBS had a significant effect on CD18 expression from the retroviral LTR.
cell^.^.^ Other studies have shown the presence of a negative
Comparison of Glvr-l and Ram-l expression. To investigate the basis for the improved transduction efficiency of the K562 and LAD EBV B-cell lines observed by using virus from PG13 producer cells as compared with that from PA317 producer cells, an assay was performed to assess the relative amounts of RNA for the amphotropic receptor for the PA317-derived vector, Ram-l, compared with the GALV receptor for the PG13-derived vector, Glvr-l. The relative amount of RNA present within a cell line should correspond with the amount of protein expressed on the cells' surface and hence the number of retroviral receptors present. Briefly, RNA from each cell line was reverse transcribed and amplified by PCR using primers designed to amplify both Glvr-l and Ram-l. The PCR reactions were end-labeled and digested with Hae 111, which cuts at different positions within each gene. The digested products were electrophoresed on 6% nondenaturing acrylamide gels to separate the fragments. Glvr-l transcription. These results indicate that the increased transduction efficiency of PG13-derived vectors compared with PA317-derived vectors is due to increased expression of Glvr-1 compared with Ram-1. Analysis of Glvr-l expression. LAD EBV B cells required multiple exposures to PG13-derived retroviral vectors to achieve transduction rates similar to those found in K562/ CD1 Ib cells after a single exposure. To investigate the basis for the increased transduction efficiency of K562/CDl l b cells as compared with LAD EBV B cells (Z) obtained by using PG13-derived vectors, RNA was prepared from K562/ CDllb cells and five different EBV B-cell lines and examined for transcription of the Glvr-l gene, which encodes the retroviral receptor required for entry of PG13 virions. Northern blotting studies showed that K562 cells express IO-fold more Glvr-l RNA than do LAD EBV B cells (Fig  6) and may explain the relative ease of K562 cell transduction by PG13-derived vectors. Glvr-l RNA was present at detectable levels in all five LAD EBV B-cell lines examined, with about threefold variation between the cell lines (Fig 6) . Additionally, very low levels of RNA encoding the amphotropic receptor Ram-l were present in these cell lines using Northern analysis (not shown).
Expression of CDlldCDI8 in Jive different LAD EBV Bcell lines.
We examined transduction efficiency in five LAD EBV B-cell lines after four exposures to LgCD18SN virus produced by PG13 cells. Cells were analyzed by FACS l week after transduction for surface expression of the CDlldCD18 heterodimer. All five lines were transduced by the LgCD18SN vector ( Table 2 ). The transduction efficiency of each cell line showed a weak correlation with Glvr-l RNA amount. We also examined the relationship of cell division rate to transduction efficiency, because vector transduction is dependent on cell repli~ation,'~ but found no relationship between doubling time and transduction efficiency ( Table 2) . These results indicate that other variables are responsible for the greater than 10-fold range in transduction rates observed in these cells.
DISCUSSION
In this report, we studied three different retroviral vectors (LgCD18SN, LgCD18, and LCD18SN) and packaged these vectors using two different retrovirus packaging cell lines (PA317 and PG13). The vectors were used to transduce K562/CDllb cells and LAD EBV B cells. The transduced cells were examined both for transduction efficiency and for levels of CD1 K D 1 8 surface expression. Modification of the tRNA PBS had no effect on expression of the CD18 gene in the cell lines tested. Similarly, removal of the neomycin phosphotransferase gene driven by the SV40 promoter from the LgCD18SN vector (to produce LgCD18) did not affect expression of the transduced CD18 gene. In both K5621 CD 1 1 b and LAD EBV B cells, the PG 13 packaged vectors showed increased transduction efficiency compared with PA317 packaged vectors, as measured by the levels of surface expression of CD 1 1/CD 18 complexes.
LAD represents a candidate disease for human gene therapy for several reasons. First, previous studies of children with the moderate disease phenotype of LAD indicate that levels of CDlUCD18 expression of 5% to 10% of normal result in only minimal episodes of severe bacterial infection.
Second, considerable clinical experience in patients with
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From CD18 GENE TRANSFER 2385 neutropenia indicate that the presence of as few as 5% of normal numbers of neutrophils is sufficient to confer adequate host defense against common bacterial pathogens. Retroviral vectors may be useful in achieving levels of gene expression in hematopoietic cells capable of therapeutic benefit to children with LAD either by providing low-level gene expression in a large number of myeloid cells or high levels of expression in a small number of mature myeloid cells.
Three previous reports have examined conditions for optimizing cell transduction and gene expression using LAD EBV B cells as a model system. The first study by Wilson et al' used a modified retroviral vector, pEMO-CD18, that contains a modified tRNA PBS using the B2 mutation3' to enhance viral expression of the CD1 8 gene. They also used an amphotropic cell line, psi-crip, to package their vector. After 72 hours of cocultivation of the EBV B cells on producer lines, they had a transduction efficiency of 2% to 4% by FACS analysis, with approximately 100% levels of CD1 8 expression. The second study by our lab5 used the LCD18SN vector packaged in PA3 17 cells to transduce LAD EBV B cells. Cocultivation of the cells for 72 hours on producer lines was performed, followed by selection of the cells for several weeks with G418. Although transduction efficiency was not measured, the level of CD18 expression was only about 5% of normal levels. This low level, in contrast to the results reported in this manuscript, may have been due to two differences in the experimental conditions: (1) a different EBV B-cell line was used in the previous study, and (2) * 1) * " in the previous study the transduced cells were selected in G418 over 3 weeks. The third study by Wilson et a13' used the retroviral vector pANZhCD18. This vector was packaged in GP+envAM12 cells. After two rounds of cocultivation of LAD EBV B cells on producer lines for 48 hours, between 55% and 60% of the cells were transduced, as determined by FACS analysis. The transduced cells expressed approximately 37% to 38% of normal CD18 expression. In summary, these reports show the variation in transduction efficiencies and CD18 gene expression that have been obtained. The work shown in this report shows that both highlevel gene expression (nearly 100% of normal levels) and a high transduction efficiency (about 25%) can be achieved using the retroviral vectors and packaging cell lines described, without the need for cocultivation with packaging cells.
Treatment of LAD by gene therapy would best be accomplished by CD18 gene transfer into hematopoietic stem cells followed by long-term expression of the gene in stem cell progeny. Hematopoietic stem cells have some properties in common with embryonic carcinoma or embryonic stem cells, which express a protein that inhibits expression from the MoMuLV-based retroviral vectors by binding to the viral tRNA primer site. Although we have found no difference in short-term assays of CD1 8 expression in K562 or LAD EBV B cells transduced with a retroviral vector with an altered tRNA primer binding site (LgCD18SN or LgCD18) compared with the unmodified vector (LCDl8SN), the altered vectors may still provide better expression over the long term after gene transfer into hematopoietic stem cells. We have found that LAD EBV B cells transduced with the PG131 LgCD18SN vector continue to express CD1 8 over a 3-month period of growth in culture, with positive cells showing nearly 100% of the wild-type CD18 expression levels (data not shown), providing preliminary evidence for lack of vector inactivation in hematopoietic cells.
In this study, we investigated the effects of the retroviral envelope used to package retroviral vectors. Previous studies using amphotropic-derived retroviral vectors resulted in variable levels of transduction efficien~y.~.'.'' We examined here gene transfer of amphotropic retroviral vectors packaged using PA317 cells to the same vectors packaged using PG13 cells. To compare the packaging cells, we packaged LgCD18SN in both the PA3 17 and PG1 3 lines. Producer lines from each packaging line were obtained and viral supernatant was used to transduce LAD EBV B cells or K562 cells containing the CD1 l b subunit. Transduction efficiency, as shown by FACS analysis, indicated that PG13 packaged lines were superior to PA317 packaged lines (Table 1 and Figs 2 and 3) , in which about 25% of K5621CDllb cells and LAD EBV B cells were transduced, as compared to less than 4% transduction with PA317 producer lines. The superior transduction efficiency of PG13-derived vectors was also found in soft agar colony assays, in which G418-resistant colonies of K562 cells transduced with PG131 LgCDl8SN were greater than threefold more abundant than PA317LgCD18SN transduced cell colonies.
To assess the reason for the high transduction efficiency of
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From the K562 cells and LAD EBV B cells using PG13 packaged vectors, we investigated whether the levels of viral receptor expression correlated with transduction efficiency. Glvr-l RNA was eightfold more abundant than Ram-I in K562 cells and, on average, about 20-fold more abundant in five LAD EBV B-cell lines. A DNA probe derived from the Glvr-l cDNA was used on Northern blots to examine RNA levels of this receptor in different cell lines. Northern blots of these cell lines indicated that the K562/CDI Ib cells, which were easily transduced, expressed more Glvr-l RNA than LAD EBV B cells, which were not as easily transduced. These results indicate that receptor expression levels correlate with transduction efficiency.
Recent reports indicating that Glvr-l RNA is more abundant than Ram-l RNA in bone marrow cells" led to a study by von Kalle et al.." who examined the efficacy of PG13-derived vectors in comparison to PA317-derived vectors in transducing human progenitor cells. They used several transduction conditions and found that in both short-term and long-term cultures, transduction with a PG 13-derived vector was superior to that of a PA3 17-derived vector. Their studies complement those presented in this report by indicating the effectiveness of the PG1 3-derived vectors in human progenitor cell transduction.
In conclusion, the results of this study indicate that, although retroviral vector modification to alter the viral tRNA binding site or to remove the neo selectable marker gene did not result in a significant increase in CD18 expression in hematopoietic cells in culture, the use of vectors produced by using PG13 GALV-derived retrovirus packaging cells resulted in much improved transduction efficiencies compared with the same vectors produced using the commonly used PA317 amphotropic retrovirus packaging cells. The Retrovirus receptor RNA expression in hematopoietic cell lines. Ten-microgram samples of total RNA from K562KDllb cells and five different LAD EBV B-cell lines were subjected to electrophoresis in agarose gels containing formaldehyde, transferred to a nylon membrane, and hybridized to a 227-bp Glvr-l DNA probe. After washing, the filter was exposed to x-ray film for 13 days. The Glvr-l RNAs have an apparent size of between 3.5 and 4 kb. The filter was then stripped and rehybridized to a GAPDH DNA probe (as a control for loading differences), washed and exposed overnight to x-ray film. The size of GAPDH mRNA is about 1.5 kb. 
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